Merck & Co.
AWARDS
NEWS
Merck & Co. announced that its Keytruda failed to hit its primary endpoint in the Phase III Keynote-119 clinical trial. The primary endpoint was superior overall survival compared to chemotherapy.
Merck is buying all outstanding shares of Peloton, a clinical-stage oncology company, for an upfront payment of $1.05 billion in cash. Peloton will also be eligible for another $1.15 billion based on various regulatory and sales milestones.
Almost every week, biopharma companies release results from ongoing clinical trials. Here’s a roundup of some of the top clinical trial news from the previous week.
Merck is planning a $1 billion expansion to its manufacturing facility in Elkton, Va. over the course of the next three years that will include the addition of approximately 100 new jobs, the office of the governor of Virginia announced Wednesday.
Merck and Co. announced that its investigational 15-valent pneumococcal conjugate vaccine was “noninferior” to a currently available 13-valent pneumococcal conjugate vaccine in healthy babies 6 to 12 weeks of age.
The company announced today that it had positive results in a Phase III clinical trial evaluating the drug for insomnia in patients with mild-to-moderate Alzheimer’s disease dementia.
JOBS
IN THE PRESS